Difference between revisions of "POEMS syndrome"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
|||
| Line 36: | Line 36: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | *[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21 | ||
| − | *[[Dexamethasone (Decadron)]] 40 mg PO once per | + | *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22 |
====Supportive medications==== | ====Supportive medications==== | ||
| Line 43: | Line 43: | ||
*[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO twice per day two days per week | *[[Trimethoprim/Sulfamethoxazole_(Bactrim_DS)|Cotrimoxazole]] 800 mg PO twice per day two days per week | ||
| − | ''' | + | '''28-day cycle for at least 6 cycles''' |
===References=== | ===References=== | ||
Revision as of 20:59, 27 July 2019
| Section editor | |
|---|---|
 |
Andrew J. Cowan, MD University of Washington Seattle, WA  andrewcowanmd |
POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes
1 regimens on this page
1 variants on this page
|
Guidelines
EMN
- 2018: Gavriatopoulou et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias PubMed
All lines of therapy
Rd
| back to top |
Rd: Revlimid (Lenalidomide) & low-dose dexamethasone
Regimen
| Study | Evidence |
|---|---|
| Nozza et al. 2017 | Phase II, <20 pts |
Chemotherapy
- Lenalidomide (Revlimid) 25 mg PO once per day on days 1 to 21
- Dexamethasone (Decadron) 40 mg PO once per day on days 1, 8, 15, 22
Supportive medications
- Aspirin 100 mg PO once per day
- LMWH in "intolerant" patients
- Cotrimoxazole 800 mg PO twice per day two days per week
28-day cycle for at least 6 cycles
References
- Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed